02.03.26 -- Trading Places: 2025 Intensified CDMOs Recruiting Sponsor Talent

Discover why this area is poised to become a leading hub for cell and gene therapy, as highlighted by CCS and industry experts at the 6th Annual Supply Chain Summit.

Downstream AAV manufacturing is still a major bottleneck, and solving it demands a true platform approach with standardized, scalable, data-driven CMC systems.

Ensure cell therapy products are consistently manufactured with safety, quality, and potency, supporting regulatory approval and successful clinical development.

Cell therapy stumbled in 2025. Solving the variability in starting material quality is critical to stabilizing manufacturing in 2026.

Uncover how an autologous CAR-T platform is addressing challenges in cell therapy manufacturing. A three-day process shortens cycles, improves T-cell potency and durability, and reduces costs.

Learn how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.

Explore the importance of adopting a Quality by Design (QbD) approach in the development process while integrating regulatory and CMC strategies for maximum efficiency and benefit.

Read the secrets behind successes in commercializing and producing commercial cell and gene therapies, including establishing standards of everyday, manufacturing operational excellence.

Learn how to mitigate supply chain risks for industrial alcohols and ensure workplace safety through rigorous tracking and reporting protocols.

A therapeutic developer partnered with an advanced manufacturing center to produce a novel-base editing treatment for sickle cell disease, enabling high-quality manufacturing.

Capital constraints are reshaping CDMO and pharma strategies, driving selective M&A, prioritizing partnerships, and enforcing financial discipline amid tighter investment conditions.

Observe how comprehensive R&D support advances therapeutic oligonucleotides from discovery through commercialization with tailored formulation development services across multiple modalities.

Focusing on critical parameters such as cell culture conditions, viral vector yield, and downstream purification strategies, can drive the success of scale-up and scale-down models for AAV production.

A commercial development leader outlines advanced therapy capabilities, highlights a global manufacturing network, and shares an updated view of available capacity across key facilities.